Shared decision making: Playing an active role in your treatment
Produced in collaboration with the Depression and Bipolar Support Alliance.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Many people who live with major depressive disorder (MDD) have trouble finding the treatment combination that will be the most effective for them. A difficult journey from the start, the trial and error involved in finding the best treatment is even more challenging without clear communication with your health care provider. Knowing the right questions to ask and the kinds of feedback you need to give is necessary in order to have the best possible outcomes.
If you or someone you love has major depressive disorder, please join NeuroCareLive and the Depression and Bipolar Support Alliance (DBSA) for an online education program with leading clinicians and patient advocates on Thursday, February 15 from 11:00AM to 12:00PM ET.
Register here to join the live program or watch it on demand after.
The three-part program is free and includes a video lecture, interactive slide presentation and Q&A sessions. Come away empowered to help yourself or someone you care for.
This three-part program covers:
- Communicating with your healthcare team about your depression and playing an active role in your treatment
- Understanding the pros and cons of your treatment options
- What to expect over the long-term and the importance of adhering to treatment
Take Control of Your Depression with Your Health Care Provider: Chapters 1 - 4
Knowing your treatment options
Understanding what to expect from treatment
Self-Care, Resources, and Frequently Asked Questions for MDD
Richard Kravitz, MD, MSPH
UC Davis Medical Center
Richard L. Kravitz, MD, MSPH, is professor and co-vice chair (research) in the Department of Internal Medicine at the University of California, Davis, and director, UC Center Sacramento. He is a general internist with research interests in physician and patient behavior, mental health in primary care, and individualization of treatment. He has led several federally funded projects focused on the role of patients and families in diagnosing and treating depression and addressing suicide risk in primary care settings. Dr Kravitz is co-editor-in-chief of the Journal of General Internal Medicine, a fellow of the American College of Physicians and AcademyHealth, and a member of the Society of General Internal Medicine. He received his medical degree from UC San Francisco School of Medicine.
Michael E. Thase, MD
Philadelphia VA Medical Center
Michael E. Thase, MD, is professor of psychiatry and director of the Mood and Anxiety Section in the department of psychiatry at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and directs the Mood Disorders Research studies at the Philadelphia Veterans Affairs Medical Center. Dr Thase’s research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder. He has authored or co-authored 16 books, numerous scientific articles and book chapters, and is involved in several professional organizations that include the American Psychiatric Association, the American Society of Clinical Psychopharmacology, and the National Depression and Bipolar Support Alliance.
Depression and Bipolar Support Alliance (DBSA)
Allen Doederlein is the external affairs executive vice president for the Depression and Bipolar Support Alliance (DBSA) in Chicago, Illinois. Mr Doederlein fundraises, facilitates the DBSA’s organizational alliances and strategic partnerships, and works with the board, scientific advisory board, staff and volunteers to transform the challenges, concerns, and contributions of people with mood disorders into meaningful change in experience, treatment, and representation of these conditions. He is a member of the International Society of Bipolar Disorders’ Advocacy Committee, and represents DBSA within the American Medical Association’s Major Depressive Disorder Committee and work groups.